<DOC>
	<DOCNO>NCT00373217</DOCNO>
	<brief_summary>RATIONALE : Vaccines make peptide may help body build effective immune response kill tumor cell . Drugs use chemotherapy , paclitaxel carboplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving chemotherapy surgery may make tumor small reduce amount normal tissue need remove . Giving vaccine therapy chemotherapy surgery may kill tumor cell remain surgery . PURPOSE : This phase II trial study well give vaccine therapy together paclitaxel carboplatin work treat patient undergo surgery stage III stage IV ovarian cancer , primary peritoneal cancer , fallopian tube cancer .</brief_summary>
	<brief_title>Vaccine Therapy , Paclitaxel , Carboplatin Treating Patients Who Are Undergoing Surgery Stage III Stage IV Ovarian Cancer , Primary Peritoneal Cancer , Fallopian Tube Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine immunogenicity vaccine therapy comprise synthetic ovarian cancer-associated peptide administer synthetic tetanus toxoid helper peptide emulsify Montanide ISA-51 paclitaxel carboplatin patient stage III-IV ovarian epithelial , primary peritoneal cavity , fallopian tube cancer undergo optimal cytoreductive surgery . OUTLINE : This open-label study . Patients assign 1 2 treatment group . - Group 1 : - Neoadjuvant chemotherapy : Patients receive paclitaxel IV 3 hour carboplatin IV 30 minute day 1 . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . Patients proceed surgical debulking . - Surgical debulking : Patients undergo primary optimal cytoreductive surgery . - Vaccine therapy : Within 14 day surgery , patient receive vaccine therapy comprise synthetic ovarian cancer-associated peptide , MAGE-A1:161-169 , FBP:1901-199 , Her-2/neu:369-377 , MAGE-A1:96-104 , Her-2/neu:754-762 , tetanus toxoid helper peptide emulsify Montanide ISA-51 intradermally subcutaneously day 1 , 8 , 15 . Treatment repeat every 14 week 2 course . - Adjuvant chemotherapy : Patients receive 4 course paclitaxel carboplatin neoadjuvant chemotherapy completion course 1 vaccine therapy . - Group 2 : - Surgical debulking : Patients undergo up-front optimal cytoreductive surgery . Patients non-optimal primary debulking may undergo interval debulking surgery within 6 week complete course 4 adjuvant chemotherapy . If interval debulking surgery perform , tumor and/or lymph node tissue collect . - Vaccine therapy : Patients receive 2 course vaccine therapy group 1 . - Adjuvant chemotherapy : Patients receive paclitaxel carboplatin group 1 , neoadjuvant chemotherapy . Treatment repeat every 21 day 8 course . Patients undergo periodic blood tumor tissue collection study correlative immunological analysis . After completion study treatment , patient progressive disease follow 30 day every six month thereafter . All patient follow every 3 month 36 month disease progression another therapy initiate , every six month thereafter . PROJECTED ACCRUAL : A total 28 patient accrue study .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis ovarian epithelial , primary peritoneal cavity , fallopian tube cancer Stage III IV disease HLAA1 , A2 , and/or A3 positive Must least 1 undissected axillary inguinal lymph node basin No recurrent disease PATIENT CHARACTERISTICS : ECOG performance status 02 Hemoglobin ≥ 8.0 g/dL WBC &gt; 3,000/mm^3 Absolute neutrophil count &gt; 1,500/mm^3 Hemoglobin A1c &lt; 7 % AST ALT ≤ 2.5 time upper limit normal ( ULN ) Bilirubin ≤ 2.5 time ULN Creatinine ≤ 1.5 time ULN HIV negative Hepatitis C negative No known suspect allergy component study vaccine No concurrent malignancy ( except nonmelanoma skin cancer ) unless patient curatively treat disease free ≥ 5 year No active serious infection No autoimmune disorder visceral involvement No prior active autoimmune disorder require cytotoxic immunosuppressive therapy The following immunologic condition allow : Laboratory evidence autoimmune disease ( e.g. , positive antinuclear antibody titer ) without symptom Clinical evidence vitiligo Other form depigmenting illness Mild arthritis require NSAIDs No New York Heart Association class III IV heart disease Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No medical contraindication potential problem would preclude study compliance PRIOR CONCURRENT THERAPY : At least 2 week since prior concurrent chemotherapy , radiotherapy , immunotherapy ( e.g. , interferon , tumor necrosis factor , interleukin , monoclonal antibody ) More 4 week since prior concurrent investigational agent More 4 week since prior concurrent allergy desensitization injection More 4 week since prior concurrent oral parenteral systemic corticosteroid No prior concurrent inhale corticosteroid ( e.g. , fluticasone salmetrol , fluticasone , triamcinolone acetonide ) Prior concurrent topical corticosteroid allow No prior vaccination MAGEA1:161169 , FBP:1901199 , Her2/neu:369377 , MAGEA1:96104 , Her2/neu:754762 More 4 week since prior concurrent growth factor ( e.g. , epoetin alfa , darbepoetin alfa , pegfilgrastim ) No concurrent treatment recurrent disease No concurrent nitrosoureas No concurrent illegal drug use Concurrent nonsteroidal antiinflammatory drug ( NSAIDs ) , antihistamine , chronic medication , unless exclude , allow Shortterm therapy acute condition specifically related ovarian cancer allow</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>fallopian tube cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
</DOC>